Healthy volunteers needed to test copycat arthritis drug
NCT ID NCT07200986
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 27 times
Summary
This study tests whether a new biosimilar drug, CT-P52, works like the approved drug Taltz in healthy adults. About 218 participants aged 19 to 55 will receive a single dose of either CT-P52 or Taltz. Researchers will compare how the drug moves through the body and check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea
-
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea
-
Inje University Busan Paik Hospital
Busan, Busanjin-gu, South Korea
-
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
-
Seoul National University Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.